Diabetes tipo 2. ¿Nuevas alternativas?

Un articulo reciente en la revista BMJ, os dejo la referencia BMJ 2012; 344:e1369. Titulado Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systemativ review and meta-analysis.  http://www.bmj.com/content/344/bmj.e1369

Las Gliptinas son menos eficaces que la metformina en monoterapia,. cuando se utiliza combinada con metformina presenta algunas ventajas y algunas deventajas en comparación con otras combinaciones.

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

Conclusion In patients with type 2 diabetes who do not achieve the glycaemic targets with metformin alone, DPP-4 inhibitors can lower HbA1c, in a similar way to sulfonylureas or pioglitazone, with neutral effects on body weight. Increased unit cost, which largely exceeds that of the older drugs, and uncertainty about their long term safety, however, should also be considered.